Want to join the conversation?
$ALXN said that the European Commission has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease. ALXN1007 is currently being evaluated in a Phase 2 study in patients with newly diagnosed acute GI-GVHD.
Looking forward for $STT’s 2017 first quarter earnings results. Is it possible for them to outperform their estimates?
$HAL has cautioned that its 1Q profit is likely to miss projections. I’m expecting EPS to be in low single digits.!
$GOOG is losing more advertisers after the boycotts over extremist ads. Future is not so bright for Google in the advertising sector..!